The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.

Autor: Cerhan JR; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Maurer MJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Link BK; Department of Internal Medicine, Division of Hematology, Oncology, and Bone & Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA., Feldman AL; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA., Habermann TM; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Jaye DL; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA., Burack WR; Department of Pathology, University of Rochester, Rochester, New York, USA., McDonnell TJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chapman JR; Department of Pathology, Division of Hematopathology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA., Syrbu S; Department of Pathology, University of Iowa, Iowa City, Iowa, USA., Vij KR; Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA., Inghirami G; Department of Pathology, Weill Cornell Medicine, New York, New York, USA., Leonard JP; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Bernal-Mizrachi L; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Farooq U; Department of Internal Medicine, Division of Hematology, Oncology, and Bone & Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA., Witzig TE; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Weiner GJ; Department of Internal Medicine, Division of Hematology, Oncology, and Bone & Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA., Wang Y; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Alderuccio JP; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA., Slager SL; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Larson MC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Riska SM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Gysbers BJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Lunde JJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Reicks TW; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Ayers AA; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., O'Leary CB; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Yost KJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Liu H; Department of Artificial Intelligence & Informatics, Mayo Clinic, Rochester, Minnesota, USA., Nowakowski GS; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Ruan J; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Koff JL; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Casulo C; Wilmot Cancer Institute, University of Rochester, Rochester, New York, USA., Thompson CA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Cohen JB; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Kahl BS; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lossos IS; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA., Friedberg JW; Department of Artificial Intelligence & Informatics, Mayo Clinic, Rochester, Minnesota, USA., Martin P; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Flowers CR; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: American journal of hematology [Am J Hematol] 2024 Mar; Vol. 99 (3), pp. 408-421. Date of Electronic Publication: 2024 Jan 13.
DOI: 10.1002/ajh.27202
Abstrakt: To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18-99). Participants came from 49 US states and included 538 Black/African-Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population-based SEER data (2015-2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population-based SEER rates for indolent B-cell (follicular and marginal zone) and T-cell lymphomas, but were 10%-15% higher than SEER rates for aggressive B-cell subtypes (diffuse large B-cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: